Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.29) per share which missed the analyst consensus estimate of $(1.14) by 13.06 percent. This is a 7.19 percent increase over losses of $(1.39) per share from the same period last year. The company reported quarterly sales of $207.000 million which beat the analyst consensus estimate of $196.971 million by 5.09 percent. This is a 25.55 percent increase over sales of $164.877 million the same period last year.